Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Intrauterine pregnancy confirmed by ultrasound~2. Estimated gestational age between 12-28 weeks~3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test~4. 16 years of age or older~5. Residency within 30 km of the study clinic~6. Provision of informed consent~7. Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol~8. Plan to deliver in the hospital~Exclusion Criteria:~1. History of serious adverse event to TS or DP~2. Refusal to take cART during pregnancy or as part of routine HIV care~3. Active medical problem requiring inpatient evaluation at the time of screening~4. Intention of moving more than 30 km from the study clinic~5. Active WHO stage 4 condition not stable under treatment~6. Signs or symptoms of early or active labor~7. Currently on ritonavir~8. Currently taking drugs associated with known risk of Torsades de pointes~9. Currently taking CYP3A inhibitor medications which potentially inhibit the metabolism of piperaquine~10. History of cardiac problems or fainting

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Daily TS + Monthly DP pregnancy (Type: ACTIVE_COMPARATOR): Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
- Daily TS + DP Placebo pregnancy (Type: PLACEBO_COMPARATOR): Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).